SPRY2
Overview
SPRY2 (Sprouty RTK Signaling Antagonist 2) encodes a negative regulator of receptor tyrosine kinase (RTK) signaling that modulates the RAS/MAPK pathway. SPRY2 expression was identified in pharmacogenomic profiling as one of several predictive features for MEK inhibitor sensitivity across cancer cell lines, consistent with its role as an attenuator of oncogenic RAS signaling.
Alterations observed in the corpus
- SPRY2 expression was identified as an additional predictive feature for MEK inhibitor sensitivity in the Cancer Cell Line Encyclopedia pharmacogenomic profiling of 947 cell lines across 24 drugs PMID:22460905
Cancer types (linked)
- No cancer-type-specific prevalence data in the current corpus.
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data in the current corpus.
Therapeutic relevance
- SPRY2 expression is among the predictive genomic features associated with MEK inhibitor sensitivity (alongside PTEN and PTPN5) in large-scale pharmacogenomic profiling; mechanistic basis not validated in this dataset PMID:22460905
Open questions
- Whether SPRY2 expression is predictive of MEK inhibitor sensitivity independent of BRAF/NRAS mutation status has not been formally tested.
Sources
This page was processed by entity-page-writer on 2026-05-06.